Neurogene (NGNE) Short term Debt (2013)

Neurogene (NGNE) posted Short term Debt of $250000.0 for Q4 2013.

Neurogene (NGNE) Short term Debt (2013) Analysis & Trends

Neurogene's Short term Debt history runs 1 years deep, the most recent figure standing at $250000.0 for Q4 2013.

Quarterly Short term Debt changed N/A year-over-year to $250000.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $250000.0 (changed N/A YoY) and the FY2013 annual result came in at $250000.0, changed N/A from the prior year.
Short term Debt was $250000.0 for Q4 2013 at Neurogene.
Across five years, Short term Debt topped out at $250000.0 in Q4 2013 and bottomed at $250000.0 in Q4 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Neurogene	17.50 Mn	17.50 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2013	250,000.00